NEWARK, Calif., April 25, 2022 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced topline results from the Phase 2 IDEAL study evaluating PN-943 in patients with moderate-to ...
BASEL, Switzerland--(BUSINESS WIRE)-- Polyneuron Pharmaceuticals AG, a clinical stage company and developer of a new class of biodegradable glycopolymers for the treatment of autoimmune diseases, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results